1987
DOI: 10.1016/0042-6822(87)90171-1
|View full text |Cite
|
Sign up to set email alerts
|

Establishment and biological characterization of an in vitro human cytomegalovirus latency model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
46
0

Year Published

1990
1990
2019
2019

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 69 publications
(47 citation statements)
references
References 24 publications
1
46
0
Order By: Relevance
“…We retain this discrepancy only apparent since thyroid carcinoma cell lines, even deriving from differentiated tumours, cannot be completely compared to surgically removed tumours. In fact, these cell lines harbour p53 mutations that are rare in thyroid differentiated neoplasias (Tanaka et al, 1987;Estour et al, 1989;Pang et al, 1989;Ito et al, 1992;Dobashi et al, 1993;Donghi et al, 1993;Fagin et al, 1993;Zeki et al, 1993;Fabien et al, 1994;Matias-Guiu et al, 1994;Ain et al, 1997;Fiore et al, 1997;Basolo et al, 2002) and they have a high proliferation rate. However, this consideration does not exclude the validity of the use of the thyroid carcinoma cell lines as experimental model to draw new information that, however, need to be subsequently validated on fresh tumours.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We retain this discrepancy only apparent since thyroid carcinoma cell lines, even deriving from differentiated tumours, cannot be completely compared to surgically removed tumours. In fact, these cell lines harbour p53 mutations that are rare in thyroid differentiated neoplasias (Tanaka et al, 1987;Estour et al, 1989;Pang et al, 1989;Ito et al, 1992;Dobashi et al, 1993;Donghi et al, 1993;Fagin et al, 1993;Zeki et al, 1993;Fabien et al, 1994;Matias-Guiu et al, 1994;Ain et al, 1997;Fiore et al, 1997;Basolo et al, 2002) and they have a high proliferation rate. However, this consideration does not exclude the validity of the use of the thyroid carcinoma cell lines as experimental model to draw new information that, however, need to be subsequently validated on fresh tumours.…”
Section: Discussionmentioning
confidence: 99%
“…The human thyroid carcinoma cell lines used in this study are: TPC-1 (Tanaka et al, 1987), WRO (Estour et al, 1989), NPA and ARO (Pang et al, 1989), FRO (Fagin et al, 1993), NIM 1 (Zeki et al, 1993), B-CPAP (Fabien et al, 1994), FB-1 (Fiore et al, 1997), FB-2 (Basolo et al, 2002), Kat-4 and Kat-18 (Ain et al, 1997). They were grown in DMEM (Gibco Laboratories, Carlsbad, CA, USA) containing 10% fetal calf serum (Gibco Laboratories), glutamine (Gibco Laboratories) and ampicillin/streptomycin (Gibco Laboratories) in a 5% CO 2 atmosphere.…”
Section: Cell Culture and Transfectionsmentioning
confidence: 99%
“…The human thyroid carcinoma cell lines studied were: TPC-1 (Tanaka et al, 1987), WRO (Pang et al, 1989), NPA (Estour et al, 1989), ARO (Pang et al, 1989), FRO (Fagin et al, 1993), NIM 1 (Zeki et al, 1991) and B-CPAP (Fabien et al, 1994). They were grown in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal bovine serum.…”
Section: Cell Culture and Assay Of The Transformed Statementioning
confidence: 99%
“…To check the ampli®cation sensitivity of each gene, we performed RT-PCR ampli®cation using RNA from TPC-1 and K562 cell lines. The TPC-1 cell, established from papillary adenocarcinoma of thyroid (Tanaka et al, 1987) and having a rearranged H4-RET oncogene (Ishizaka et al, 1989(Ishizaka et al, , 1990, and the K562 cell line having a BCR ± ABL gene derived from CML (Lozzio and Lozzio, 1975), were used as positive controls. PCR primers used in this study were obtained from Biologica (Nagoya, Japan) and their sequences are listed in Table 3.…”
Section: Reverse Transcription Pcr (Rt-pcr)mentioning
confidence: 99%